Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $141.10 USD
Change Today -4.84 / -3.32%
Volume 2.0M
ILMN On Other Exchanges
As of 1:57 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

illumina inc (ILMN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/20/15 - $242.37
52 Week Low
10/6/15 - $130.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ILLUMINA INC (ILMN)

illumina inc (ILMN) Details

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company’s products include sequencing platforms that are based on its SBS technology, which provides researchers with various ranges of applications and the ability to sequence mammalian genomes; and array platforms consist of HiScan and iScan systems, as well as NextSeq 550 system that are array scanners for DNA and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis. It also offers various library preparation and sequencing kits to simplify workflows and accelerate analysis. In addition, the company provides genotyping, noninvasive prenatal test, and whole-genome sequencing services. It serves genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company sells its products directly, as well as through distributors. It has a collaboration agreement with Merck Serono to develop a sequencing-based oncology diagnostic; Burning Rock to develop molecular diagnostics for oncology; and Memorial Sloan Kettering Cancer Center to develop of strategies to diagnose and monitor cancer, and establish ctDNA as an important marker in the study and eventual treatment of cancer. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

3,700 Employees
Last Reported Date: 02/18/15
Founded in 1998

illumina inc (ILMN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $859.2K
President and Director
Total Annual Compensation: $689.2K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $463.3K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $467.5K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $403.7K
Compensation as of Fiscal Year 2014.

illumina inc (ILMN) Key Developments

Illumina Introduces Genomics Solutions to Advance Clinical Research

Illumina Inc. announced the launch of new TruSeq® library preparation kits and Infinium® arrays that enable researchers to explore genetic variation on a more comprehensive scale. The new additions to the application-driven portfolio address a broad range of genetic studies from whole exome to population and disease specific genotyping, leveraging the Illumina portfolio of genomic analysis systems. Illumina will highlight these new genomic solutions at the 2015 American Society of Human Genetics meeting on October 6 - 10 at Booth #411. The following new products are intended for use with Illumina next-generation sequencing (NGS) systems and are complemented by new data analysis applications available on Illumina's BaseSpace cloud computing platform.

Illumina Inc. Provides Preliminary Revenue Guidance for the Third Quarter Ended September 27, 2015 and for the Fourth Quarter of 2015; Provides Earnings Guidance for the Third Quarter Ended September 27, 2015; Revises Revenue Guidance for the Full Year Fiscal 2015; Reaffirms Revenue Guidance for the Full Year Fiscal 2016

Illumina Inc. provided preliminary revenue guidance for the third quarter ended September 27, 2015. The company estimated third quarter revenue of approximately $550 million, a 14% increase compared to $481 million in the third quarter of 2014 and 18% growth on a constant currency basis. For the third quarter, the company expects non-GAAP EPS to come in below the current consensus expectations, consistent with the 3% revenue shortfall. For fiscal 2015, the company now projects approximately 18% total revenue growth below original expectation of 20%. On a constant currency basis, this equates to approximately 21% growth year-over-year based on current exchange rates. For the fourth, the company expects revenue of approximately $570 million. Importantly, the factors contributing to the third quarter shortfall do not dampen long-term expectations for revenue growth, which remain at 15% to 20% through 2016.

Illumina Inc. to Report Q3, 2015 Results on Oct 05, 2015

Illumina Inc. announced that they will report Q3, 2015 results at 1:30 PM, Pacific Standard Time on Oct 05, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILMN:US $141.10 USD -4.84

ILMN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 4,225 INR +29.65
Hologic Inc $36.86 USD -0.62
Sigma-Aldrich Corp $139.59 USD +0.015
Symrise AG €56.00 EUR +0.38
Waters Corp $118.40 USD -1.16
View Industry Companies

Industry Analysis


Industry Average

Valuation ILMN Industry Range
Price/Earnings 49.9x
Price/Sales 11.4x
Price/Book 13.2x
Price/Cash Flow 44.7x
TEV/Sales 10.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ILLUMINA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at